☰

Nanovery

Updating the operating model

Industry
Biotechnology
Public information as of
January 2026

A4BEE prepared this analysis from publicly available sources. It reflects our own reading of Nanovery's published strategy and is not endorsed by, or produced in cooperation with, Nanovery. Company website

Strategic priorities

Nanovery operates across 4 stated priorities, with the most concrete near-term plan anchored on commercial scaling.

Transition from research-led startup to market leadership through appointment of its founder as CEO and securing GBP 1.1M expansion funding from Northstar Ventures and Smartlink.

Expansion of analytical capabilities to include double-stranded siRNA detection and exotic chemical modifications such as LNA, MOe, fluoro, and OME sequences.

Refining the "Design-Build-Test-Learn" cycle using AI and molecular dynamics to automate assay development and deliver validated assays within 30 days of initial contact.

Challenges we see

  • Digital R&D

    Molecular Programming Complexity

    The development of Nucleic Acid Nanorobots (NANs) requires predicting the behavior of synthetic DNA sequences in diverse biological environments. Each nanorobot must maintain high sensitivity and precise selectivity even for single nucleotide variations.

    The enzyme-free amplification platform requires high-intensity computational modeling and iterative testing, creating bottlenecks in the 30-day assay development timeline.

  • Digital Integration

    Legacy Laboratory Infrastructure

    Nanovery's sophisticated NAN platform must interface with traditional laboratories that remain dependent on paper-based data collection and legacy SCADA systems. Industry data shows 57% of lab staff cite lack of specialized knowledge as a barrier to digital transformation.

    Customer adoption is slowed by the "digital divide" where clients are not ready for high-throughput, AI-driven automation despite 92% expecting data platforms to become standard within two years.

  • Compliance Regulatory

    GxP Compliance and Audit Trails

    Meeting GxP compliance requirements for clinical use demands rigorous documentation and auditable data requirements. The Assay Validation Scientist role focuses on technology transfer to manufacturing under quality management systems (QMS).

    Manual QMS processes and the complexity of assay validation increase time-to-market and resource expenditure, risking competitive positioning against established bioanalysis providers.

  • Operations Manufacturing

    Supply Chain Dependencies

    Nanovery's 30-day assay development cycle depends on sourcing high-quality oligonucleotide components from third-party providers. The manufacturing of nanorobots requires specialized chemical modifications with precise specifications.

    External oligo sourcing introduces a 2-3 week lead time that consumes the majority of the promised 30-day development window, limiting capacity for rapid customer response.

  • Operations Organizational

    Research-to-Commercial Transition

    The departure of the former CEO in early 2025 and subsequent restructuring signaled a fundamental shift from boutique R&D operations to a scalable technology platform provider. The team currently operates with "overcaffeinated scientists wrestling with words" for quarterly communications.

    The transition from research-led to commercial-led culture drives internal friction and operational inefficiencies where digital administrative burdens and manual processes are not systematically addressed.

Opportunities, by urgency and business impact

Each bubble is one opportunity, numbered to match the list below. Further right means it bites sooner; higher means a bigger effect on the business. A bigger bubble means a bigger implementation effort.

Source: A4BEE analysis of public sources

  1. Manual Laboratory Data Management

    Nanovery's laboratory operations still rely on manual data collection and siloed experimental data systems. Scientists spend significant time on data entry and reconciliation rather than molecular design and analysis.

    Implementing an automated data capture system connecting laboratory instruments to a unified data platform would eliminate manual errors and free scientists to focus on core R&D activities.

  2. Regulatory Documentation Burden

    Current QMS and regulatory documentation processes are manual and paper-based, creating compliance risks and consuming valuable R&D resources. Technology transfer to manufacturing requires extensive documentation overhead.

    Deploying an ontology-driven data lakehouse would automate GxP audit trails and reduce regulatory reporting time by up to 75%, ensuring compliance while accelerating time-to-market.

  3. Molecular Simulation Bottlenecks

    Predicting NAN behavior in complex biological media such as blood serum and tissue requires intensive computational modeling. Current in silico pipelines require continuous updates to accommodate exotic chemical modifications.

    Building a Digital Twin platform for molecular dynamics would enable Nanovery to simulate nanorobot reactions in virtual environments, de-risking laboratory experiments and accelerating the Design-Build-Test-Learn cycle.

  4. Legacy Equipment Integration

    Customers seeking to adopt NAN-based bioanalysis often operate with outdated laboratory infrastructure not designed for high-throughput digital workflows. This creates adoption friction and extends deployment timelines.

    Developing IT/OT retrofitting solutions with OPC UA protocols would enable Nanovery's platform to integrate smooth with existing customer equipment, lowering barriers to adoption and expanding addressable market.

  5. Scalable Manufacturing Infrastructure

    Transitioning from pilot-scale assay development to high-throughput manufacturing requires automated process orchestration. Current manual process steps limit production capacity and introduce variability.

    Implementing automated process orchestration with integrated Process Analytical Technology (PAT) would remove up to 80% of manual steps and reduce experiment time by 60%, enabling Nanovery to scale production for global pharmaceutical partnerships.

What we'd propose

  • Digital Lab

    Digital Lab Ecosystem Integration

    A comprehensive laboratory digitization solution that connects diverse instruments, automates data collection, and eliminates paper-based workflows to create a unified digital workspace for NAN development.

    • Unified data backbone

      Connect instruments and LIMS into a single data spine so QC and CDMO records are queryable across sites.

      DETAIL

    • Paperless workflows

      Move lab execution from paper to instrument-captured records with full audit trail.

      DETAIL

    • Continuous QC release

      Review-by-exception dashboards that flag only the records needing scientist attention.

      DETAIL

    • Shorter lead time from data capture to decision.
    • Records that audit on their own, not on inspection day.
    • Scale without adding the same headcount.

    We've done this before

    See how we do Digital Lab
  • Enterprise AI

    Ontology-Driven Compliance Platform

    An intelligent data lakehouse architecture that establishes a Single Source of Truth for all experimental and regulatory data, automating GxP compliance and audit trail generation.

    • Ontology layer

      A shared semantic model so lab, process, and quality data describe the same things the same way.

      DETAIL

    • Predictive models

      Models trained on the historical data plane that flag deviations before they become scrap.

      DETAIL

    • Decision surfaces

      Single pane of glass that surfaces model output to the right role at the right moment.

      DETAIL

    • Shorter lead time from data capture to decision.
    • Records that audit on their own, not on inspection day.
    • Scale without adding the same headcount.

    We've done this before

    See how we do Enterprise AI
  • Digital Lab

    Molecular Digital Twin Platform

    A cloud-based digital twin environment that enables in silico simulation of NAN behavior in complex biological media, accelerating the Design-Build-Test-Learn cycle and de-risking physical experiments.

    • Unified data backbone

      Connect instruments and LIMS into a single data spine so QC and CDMO records are queryable across sites.

      DETAIL

    • Paperless workflows

      Move lab execution from paper to instrument-captured records with full audit trail.

      DETAIL

    • Continuous QC release

      Review-by-exception dashboards that flag only the records needing scientist attention.

      DETAIL

    • Shorter lead time from data capture to decision.
    • Records that audit on their own, not on inspection day.
    • Scale without adding the same headcount.

    We've done this before

    See how we do Digital Lab
  • Digital CDMO

    Legacy Equipment Retrofitting Solution

    An IT/OT integration service that enables Nanovery's NAN platform to interface smooth with customer laboratory equipment through protocol bridging and smart connectivity modules.

    • OT/IT convergence

      Pull sensor and controller data off the line into a shared data plane in real time.

      DETAIL

    • Batch intelligence

      Golden-batch comparison and deviation detection running on the same data plane.

      DETAIL

    • Production release flow

      Closed-loop between QA, MES, and ERP so batch record review and release follow the data, not the paperwork.

      DETAIL

    • Shorter lead time from data capture to decision.
    • Records that audit on their own, not on inspection day.
    • Scale without adding the same headcount.

    We've done this before

    See how we do Digital CDMO
  • Digital Lab

    Automated Production Orchestration

    A closed-loop process control system that automates assay kit manufacturing through integrated Process Analytical Technology, removing manual interventions and enabling consistent high-throughput production.

    • Unified data backbone

      Connect instruments and LIMS into a single data spine so QC and CDMO records are queryable across sites.

      DETAIL

    • Paperless workflows

      Move lab execution from paper to instrument-captured records with full audit trail.

      DETAIL

    • Continuous QC release

      Review-by-exception dashboards that flag only the records needing scientist attention.

      DETAIL

    • Shorter lead time from data capture to decision.
    • Records that audit on their own, not on inspection day.
    • Scale without adding the same headcount.

    We've done this before

    See how we do Digital Lab

Digital maturity: today and target

Scored out of 100 across six dimensions. The target is what Nanovery's own published ambition implies — not a perfect score.

Source: A4BEE analysis of public sources
Data Integration 45 → 90
Siloed computational and experimental data with some manual collection; target is 100% unified IoT/OT data gateway communication
Regulatory Compliance 40 → 85
Manual QMS and technology transfer documentation; target is automated ontology-driven GxP audit trails and reporting
Predictive Modeling 60 → 95
Advanced molecular dynamics for NAN design exists; target is full Digital Twin platform with predictive process optimization
Workflow Automation 50 → 90
Some automated validation platforms in use; target is closed-loop control systems removing 80% of manual steps
User Experience 35 → 80
High reliance on specialized PhD scientists for operations; target is intuitive HMIs enabling broader team participation
Infrastructure Scalability 40 → 85
Research-focused infrastructure with single points of failure; target is cloud-ready high-availability cluster architecture

Check this yourself

Our Service Portal has free self-assessments and market comparisons. These are the ones that line up with what we've read above — no sales call required.

Think we've read this right?

Talk to us

Related reading

This is an independent analysis prepared by A4BEE from publicly available information as of January 2026. It reflects A4BEE's own interpretation and opinion, is not affiliated with, endorsed by, or verified with Nanovery, and may be incomplete or inaccurate. All company names and trademarks are the property of their respective owners. To request a correction or removal, contact [email protected].